{"id":8595,"date":"2024-09-26T18:15:22","date_gmt":"2024-09-26T15:15:22","guid":{"rendered":"https:\/\/bricswomen.com\/?post_type=project&#038;p=8595"},"modified":"2024-09-26T18:20:07","modified_gmt":"2024-09-26T15:20:07","slug":"creation-of-thematic-pharma-clustersfor-development-and-organizationof-innovative-drug-products-production","status":"publish","type":"project","link":"https:\/\/bricswomen.com\/pt\/project\/creation-of-thematic-pharma-clustersfor-development-and-organizationof-innovative-drug-products-production\/","title":{"rendered":"Cria\u00e7\u00e3o de clusters farmac\u00eauticos tem\u00e1ticos para desenvolvimento e organiza\u00e7\u00e3o da produ\u00e7\u00e3o de medicamentos inovadores"},"content":{"rendered":"<button class=\"simplefavorite-button\" data-postid=\"8595\" data-siteid=\"1\" data-groupid=\"1\" data-favoritecount=\"3\" style=\"\"><i class=\"sf-icon-star-empty\"><\/i><\/button>\n<p>Em 2024, o Cap\u00edtulo BRICS WBA da R\u00fassia iniciou o projeto \u201cCria\u00e7\u00e3o de clusters farmac\u00eauticos tem\u00e1ticos para desenvolvimento e organiza\u00e7\u00e3o da produ\u00e7\u00e3o de medicamentos inovadores\u201d no \u00e2mbito do grupo de trabalho sobre sa\u00fade.<\/p>\n\n\n\n<p>A cria\u00e7\u00e3o de clusters farmac\u00eauticos tem\u00e1ticos permitir\u00e1 combinar as capacidades, compet\u00eancias e esfor\u00e7os de empresas dos estados-membros do BRICS para abordar os desafios de fornecer prontamente aos sistemas nacionais de sa\u00fade medicamentos de alta demanda. A combina\u00e7\u00e3o de empresas pode ser implementada na forma de alian\u00e7as internacionais.<\/p>\n\n\n\n<p>A opera\u00e7\u00e3o de alian\u00e7as internacionais otimizar\u00e1 os gastos financeiros e de tempo das empresas nacionais para o desenvolvimento, produ\u00e7\u00e3o e lan\u00e7amento de medicamentos no mercado.<\/p>\n\n\n\n<p>Definir o status desses clusters farmac\u00eauticos tem\u00e1ticos, com o apoio adequado dos pa\u00edses do BRICS, aumentar\u00e1 as oportunidades de coopera\u00e7\u00e3o e financiamento desses projetos.<\/p>\n\n\n\n<p>O estabelecimento de clusters farmac\u00eauticos tem\u00e1ticos servir\u00e1 como uma base pr\u00e1tica para o desenvolvimento de abordagens para harmonizar os requisitos regulat\u00f3rios dos estados-membros do BRICS.<\/p>\n\n\n\n<p>A l\u00edder do projeto \u00e9 a Sra. Liudmila Shcherbakova, presidente do Velpharm Group, chefe do grupo de trabalho sobre sa\u00fade do cap\u00edtulo BRICS WBA da R\u00fassia.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"877\" height=\"818\" src=\"https:\/\/bricswomen.com\/wp-content\/uploads\/2024\/04\/WhatsApp-Image-2024-04-07-at-12.21.07-AM-1.jpeg\" alt=\"\" class=\"wp-image-1463\" style=\"width:357px;height:auto\" srcset=\"https:\/\/bricswomen.com\/wp-content\/uploads\/2024\/04\/WhatsApp-Image-2024-04-07-at-12.21.07-AM-1.jpeg 877w, https:\/\/bricswomen.com\/wp-content\/uploads\/2024\/04\/WhatsApp-Image-2024-04-07-at-12.21.07-AM-1-300x280.jpeg 300w, https:\/\/bricswomen.com\/wp-content\/uploads\/2024\/04\/WhatsApp-Image-2024-04-07-at-12.21.07-AM-1-13x12.jpeg 13w\" sizes=\"auto, (max-width: 877px) 100vw, 877px\" \/><\/figure>","protected":false},"featured_media":8597,"template":"","project_tag":[],"ppma_author":[176],"class_list":["post-8595","project","type-project","status-publish","has-post-thumbnail","hentry"],"acf":[],"uagb_featured_image_src":{"full":["https:\/\/bricswomen.com\/wp-content\/uploads\/2024\/09\/2024-09-26_18-12-57-e1727363713428.jpg",1075,276,false],"thumbnail":["https:\/\/bricswomen.com\/wp-content\/uploads\/2024\/09\/2024-09-26_18-12-57-e1727363713428-250x250.jpg",250,250,true],"medium":["https:\/\/bricswomen.com\/wp-content\/uploads\/2024\/09\/2024-09-26_18-12-57-e1727363713428-300x77.jpg",300,77,true],"medium_large":["https:\/\/bricswomen.com\/wp-content\/uploads\/2024\/09\/2024-09-26_18-12-57-e1727363713428-768x197.jpg",768,197,true],"large":["https:\/\/bricswomen.com\/wp-content\/uploads\/2024\/09\/2024-09-26_18-12-57-e1727363713428-1024x263.jpg",1024,263,true],"1536x1536":["https:\/\/bricswomen.com\/wp-content\/uploads\/2024\/09\/2024-09-26_18-12-57-e1727363713428.jpg",1075,276,false],"2048x2048":["https:\/\/bricswomen.com\/wp-content\/uploads\/2024\/09\/2024-09-26_18-12-57-e1727363713428.jpg",1075,276,false],"trp-custom-language-flag":["https:\/\/bricswomen.com\/wp-content\/uploads\/2024\/09\/2024-09-26_18-12-57-e1727363713428-18x5.jpg",18,5,true],"project-slider":["https:\/\/bricswomen.com\/wp-content\/uploads\/2024\/09\/2024-09-26_18-12-57-e1727363713428-1040x276.jpg",1040,276,true]},"uagb_author_info":{"display_name":"admin","author_link":"https:\/\/bricswomen.com\/pt\/account\/?user=0"},"uagb_comment_info":0,"uagb_excerpt":"In 2024, BRICS WBA Russia Chapter initiated the project \u201cCreation of thematic pharma clusters for development and organization of innovative drug products production\u201d within the framework of the working group on healthcare. The creation of thematic pharma clusters will allow to combine the capabilities, competencies and efforts of companies from the BRICS member-states to address&hellip;","_links":{"self":[{"href":"https:\/\/bricswomen.com\/pt\/wp-json\/wp\/v2\/project\/8595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bricswomen.com\/pt\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/bricswomen.com\/pt\/wp-json\/wp\/v2\/types\/project"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bricswomen.com\/pt\/wp-json\/wp\/v2\/media\/8597"}],"wp:attachment":[{"href":"https:\/\/bricswomen.com\/pt\/wp-json\/wp\/v2\/media?parent=8595"}],"wp:term":[{"taxonomy":"project_tag","embeddable":true,"href":"https:\/\/bricswomen.com\/pt\/wp-json\/wp\/v2\/project_tag?post=8595"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/bricswomen.com\/pt\/wp-json\/wp\/v2\/ppma_author?post=8595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}